Related Guides
Continue your research with these related independent reviews.
Microdosing Semaglutide: Sub-Standard Doses, STEP Evidence & How to Start
Semaglutide microdosing — using doses below the standard 0.25mg starting point, or intentionally staying at sub-therapeutic levels for maintenance — has grown into a widespread patient practice. Here's what the STEP clinical trials actually support, the dose math for compounded vials, and which providers offer flexible dosing protocols.
STEP Trial Dose-Response Data
~5.9%
Weight loss at 0.5mg/week (68 wks)
~9.3%
Weight loss at 1.0mg/week (68 wks)
~14.9%
Weight loss at 2.4mg/week (68 wks)
Source: STEP 1–4 trials. No dedicated RCTs exist for sub-0.25mg “true microdosing.”
Lower doses still work
0.5mg produces ~40% of the weight loss of the max dose. Meaningful results without maximum side effects.
Compounded vials required
Ozempic and Wegovy pens have fixed doses. Only compounded semaglutide allows sub-0.25mg custom dosing via syringe.
Physician supervision essential
Microdosing protocols are individualized. A prescribing physician should monitor weight, side effects, and dose progression.
What “Microdosing Semaglutide” Actually Means
In the GLP-1 patient community, “microdosing” refers to one of two distinct practices:
- Sub-threshold starting doses: Beginning below the FDA-standard 0.25mg/week starting dose — for example, 0.1mg or 0.125mg — to allow gut adaptation and minimize early nausea. The patient may then titrate up on the standard schedule from a lower baseline.
- Intentional maintenance at sub-therapeutic levels: Staying at 0.25–0.5mg/week indefinitely after reaching goal weight, rather than titrating to the maximum 2.4mg. The goal is the “minimum effective dose” for weight maintenance.
Unlike tirzepatide microdosing (where the FDA starting dose is 2.5mg and “micro” means going below that), semaglutide's standard STEP trial titration already starts at 0.25mg — so the concept of microdosing overlaps with the early titration steps. The key distinction is intentionality: microdosing means staying at lower doses purposefully, not just being in the early titration phase.
Four Reasons Patients Choose Semaglutide Microdosing
Side-effect management
Patients who experience significant nausea or GI upset at 0.25mg use sub-threshold starting doses (0.1–0.125mg) to allow gut adaptation before stepping up.
Maintenance coasting
Patients who reached their goal weight at a lower dose intentionally stay there rather than pushing to maximum. Some maintain at 0.5mg indefinitely.
Tolerability ceiling
Patients who can't tolerate therapeutic doses (1.0mg+) due to chronic nausea or other side effects stabilize at whatever dose they can handle and get partial benefit.
Ultra-slow titration
Some physicians use 8–12 week holds at each dose tier instead of the standard 4-week protocol — slower onset, reduced side-effect burden, same eventual destination.
Not recommended without physician guidance: Combining semaglutide with another GLP-1 simultaneously (stacking) is not an established protocol and carries risk. All microdosing approaches should be supervised by a licensed prescriber.
The Evidence Base: What the STEP Trials Tell Us
The STEP trial program studied once-weekly subcutaneous semaglutide at doses from 0.25mg (the starting dose) up to 2.4mg (the maximum approved weight-loss dose). The 4-week titration schedule was: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg, with 4-week holds at each level.
| Dose | Approx. Weight Loss at 68 Weeks | Notes |
|---|---|---|
| Sub-0.25mg | No clinical data | No dedicated RCTs; used empirically for side-effect management |
| 0.5mg/week | ~5.9% | Meaningful loss; ~40% of max-dose benefit |
| 1.0mg/week | ~9.3% | ~62% of max-dose benefit; strong mid-range option |
| 1.7mg/week | ~12.4% | ~83% of max-dose benefit |
| 2.4mg/week (max) | ~14.9% | FDA-approved max dose for weight management |
Key takeaway: Moving from 0.5mg to 2.4mg adds roughly 9 percentage points of weight loss — meaningful, but not transformative. For patients who can't tolerate higher doses, the 0.5–1.0mg range still produces clinically significant results. There is no published data on sub-0.25mg dosing; any patient-reported benefit at that level is empirical, not trial-validated.
Why Compounded Semaglutide Enables Microdosing (Branded Pens Don't)
Branded Ozempic pens come in four fixed dose strengths: 0.25mg, 0.5mg, 1mg, and 2mg — administered via a dialed auto-injector. Wegovy pens are fixed at 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg. You cannot draw a partial or custom dose from an auto-injector pen.
Compounded semaglutide is dispensed in multi-dose vials at a specified concentration (typically 2.5mg/mL or 5mg/mL). You draw your dose using an insulin syringe, which allows precise measurement of any volume — enabling 0.1mg, 0.125mg, or any custom incremental dose.
This is the core reason microdosing protocols require compounded semaglutide. The how-to guide for measuring and injecting a microdose covers the equipment and technique in detail.
Dose Math: How to Measure Any Semaglutide Dose from a Vial
Always confirm concentration with your pharmacy — vials vary. These calculations assume standard 2.5mg/mL and 5mg/mL concentrations.
| Target Dose | 2.5 mg/mL vial — draw volume | 5 mg/mL vial — draw volume |
|---|---|---|
| 0.05mg | 0.02 mL | 0.01 mL |
| 0.1mg | 0.04 mL | 0.02 mL |
| 0.125mg | 0.05 mL | 0.025 mL |
| 0.25mg (standard start) | 0.10 mL | 0.05 mL |
| 0.5mg | 0.20 mL | 0.10 mL |
| 1.0mg | 0.40 mL | 0.20 mL |
| 1.7mg | 0.68 mL | 0.34 mL |
| 2.4mg | 0.96 mL | 0.48 mL |
Note: Sub-0.25mg draw volumes (0.02–0.05 mL) require a 1mL insulin syringe with clear 0.01mL markings. Confirm with your provider before attempting very small volumes.
Maintenance Microdosing Protocol: Stepping Down After Goal Weight
After reaching goal weight on a therapeutic dose (1.0–2.4mg), some patients and physicians use a step-down protocol to find the minimum dose needed to maintain results:
- Hold at current therapeutic dose for 4–8 weeks after reaching goal weight to confirm stability.
- Step down by one tier (e.g., 2.4mg → 1.7mg → 1.0mg → 0.5mg), holding 8–12 weeks at each level — longer than the titration-up schedule to allow metabolic adaptation.
- Monitor weekly weight. If weight rebounds more than 3–5 lbs above goal, step back up to the previous dose.
- The floor is individual. Some patients maintain at 0.5mg indefinitely; others find they need 1.0mg or higher. There is no universal maintenance dose.
Clinical note: The STEP extension data and real-world evidence consistently show that weight regain accelerates rapidly when semaglutide is discontinued entirely. A maintenance microdose — even 0.5mg — is meaningfully better than stopping.
Ultra-Slow Titration: Reducing GI Side Effects at the Cost of Slower Onset
The standard STEP titration schedule uses 4-week holds at each dose. Ultra-slow titration extends those holds to 8–12 weeks:
| Dose | Standard Hold (STEP) | Ultra-Slow Hold |
|---|---|---|
| 0.25mg | 4 weeks | 8–12 weeks |
| 0.5mg | 4 weeks | 8–12 weeks |
| 1.0mg | 4 weeks | 8–12 weeks |
| 1.7mg | 4 weeks | 8–12 weeks |
| 2.4mg | Maintenance | Maintenance |
The tradeoff: ultra-slow titration dramatically reduces nausea and GI distress but delays reaching therapeutic doses by months. Total time to reach 2.4mg on ultra-slow protocol: approximately 40–48 weeks vs. the standard 16 weeks. Many patients find this acceptable trade-off if standard titration was intolerable.
Providers That Support Semaglutide Microdosing
All require a valid prescription from a licensed prescriber. Pricing verified May 2026.
Ivim Health
Explicitly offers customized titration and microdosing semaglutide protocols. Known in the patient community for physician-supervised flexible dosing approaches that aren't available through standard telehealth providers. Pricing: verify current rates on their site.
- Custom microdosing protocols available
- Physician-supervised titration adjustments
- Compounded injectable semaglutide
Strut Health
Verified on brand site Invalid DateMost affordable compounded injectable semaglutide option. Vial-based delivery offers maximum dosing flexibility for patients who want to use precise sub-0.25mg doses. Good choice for patients who already understand the microdosing protocol and want the lowest cost access point.
- Compounded injectable semaglutide from $99/mo
- Vial + syringe — custom dose measurement possible
- Physician review included
TMates
Verified on brand site Invalid DateEstablished compounded semaglutide provider with physician-supervised programs. Physician-managed titration means microdosing requests can be accommodated during the intake consultation. Monthly subscription model with ongoing provider access.
- Compounded injectable semaglutide from $158/mo
- Ongoing provider access for dose adjustments
- Physician-supervised titration
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.
Frequently Asked Questions
What is microdosing semaglutide?
Microdosing semaglutide refers to intentionally using doses below the standard FDA-approved starting dose of 0.25mg/week, or maintaining at sub-therapeutic doses (0.25–0.5mg) long-term rather than titrating to the maximum 2.4mg/week. Patients use this approach to minimize nausea during initial titration, coast on a minimal effective maintenance dose after reaching goal weight, or manage tolerability when standard doses cause significant side effects. It requires compounded semaglutide in a multi-dose vial — branded Ozempic and Wegovy pens use fixed doses and cannot be partially administered.
How much weight loss does microdosing semaglutide produce?
The STEP clinical trials show a clear dose-response relationship: 0.5mg/week produced approximately 5.9% body weight loss at 68 weeks, 1.0mg/week produced approximately 9.3%, and the full 2.4mg/week dose produced approximately 14.9%. No dedicated randomized controlled trials exist for sub-0.25mg doses ("true microdosing"). The evidence for maintenance microdosing is stronger — patients who find a minimum effective dose and stay on it long-term can sustain their weight loss results.
Why is compounded semaglutide better for microdosing than Ozempic or Wegovy?
Branded Ozempic comes in fixed auto-injector pens (0.25mg, 0.5mg, 1mg, 2mg); Wegovy pens are similarly fixed (0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg). You cannot administer a partial dose from these pens. Compounded semaglutide is dispensed in multi-dose vials (typically 2.5mg/mL or 5mg/mL), allowing precise dose measurement with an insulin syringe. This means you can dose 0.1mg, 0.125mg, or any custom amount — which is why microdosing protocols require the compounded formulation.
What is the minimum effective maintenance dose for semaglutide?
There is no single minimum effective dose — it varies by individual. Some patients maintain their goal weight at 0.5mg/week; others require 1.0mg or higher. The clinical approach is to step down by one dose tier every 8–12 weeks after reaching goal weight and monitor for weight regain. If weight rebounds by more than 3–5 lbs, stepping back up to the previous dose is typically recommended. This protocol is individualized and should be supervised by a prescribing physician.
Which providers offer semaglutide microdosing protocols?
Ivim Health is the most well-known telehealth provider offering explicit semaglutide microdosing and customized titration protocols. Strut Health ($99/mo for injectable compounded semaglutide) is notable for dosing flexibility with vial-based delivery. TMates ($158/mo) also offers compounded semaglutide with physician-supervised protocols. All require a brief medical intake and valid prescription from a licensed prescriber.
Is ultra-slow titration the same as microdosing semaglutide?
They overlap but are not identical. Ultra-slow titration means holding at each dose level for 8–12 weeks instead of the standard 4 weeks before moving up. You may still start at 0.25mg and eventually reach the therapeutic maximum — the pace is just slower. True microdosing (in the GLP-1 patient community sense) means intentionally staying at sub-therapeutic doses either indefinitely (maintenance strategy) or starting below 0.25mg. Both require compounded semaglutide for maximum flexibility.